Pharma Mar Dividenden en inkoop
Dividend criteriumcontroles 0/6
Pharma Mar is een dividendbetalend bedrijf met een huidig rendement van 0.84%.
Belangrijke informatie
0.8%
Dividendrendement
1.0%
Terugkoop Rendement
| Totaal aandeelhoudersrendement | 1.8% |
| Toekomstig dividendrendement | 0.8% |
| Dividendgroei | 12.2% |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | €0.650 |
| Uitbetalingsratio | 1,833% |
Recente updates van dividend en inkoop
Recent updates
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Oct 16
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Jul 28Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Jun 01Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
May 28Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 28We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Mar 08Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Mar 05Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Sep 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%
May 04Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding
Mar 16Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly
Sep 08News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts
Aug 03Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock
May 31Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
May 10Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 08Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years
Jan 14Is Pharma Mar (BME:PHM) A Risky Investment?
Nov 19Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Hoewel de dividendbetalingen stabiel zijn, betaalt PHM nog geen 10 jaar dividend uit.
Groeiend dividend: De dividendbetalingen van PHM zijn gestegen, maar het bedrijf heeft pas 5 jaar dividend uitgekeerd.
Dividendrendement versus markt
| Pharma Mar Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (PHM) | 0.8% |
| Markt onderkant 25% (ES) | 2.4% |
| Markt Top 25% (ES) | 5.2% |
| Gemiddelde industrie (Biotechs) | 1.5% |
| Analist prognose (PHM) (tot 3 jaar) | 0.8% |
Opmerkelijk dividend: Het dividend van PHM ( 0.84% ) is niet noemenswaardig vergeleken met de onderste 25% van de dividendbetalers op de Spanish markt ( 2.36% ).
Hoog dividend: Het dividend PHM ( 0.84% ) is laag vergeleken met de top 25% van dividendbetalers in de Spanish markt ( 5.25% ).
Winstuitkering aan aandeelhouders
Verdiendekking: Gezien de hoge payout ratio ( 1832.8% ) worden de dividendbetalingen van PHM niet goed gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: PHM keert dividend uit, maar het bedrijf heeft geen vrije kasstromen.